Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Net Income | 30.83% | 43.10% | -10.42% | 28.99% | 13.22% |
| Total Depreciation and Amortization | -10.82% | -7.97% | -3.83% | 42.62% | -46.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.79% | -58.25% | 72.24% | -51.62% | -11.97% |
| Change in Net Operating Assets | -498.77% | 59.32% | 6.88% | -253.76% | 127.10% |
| Cash from Operations | -15.11% | 45.27% | -5.55% | 10.40% | 34.74% |
| Capital Expenditure | -- | -- | -- | -450.00% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.75% | -44.86% | -94.94% | 136.69% | 1,844.63% |
| Cash from Investing | 33.82% | -44.86% | -94.91% | 135.88% | 1,729.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 35.17% | -2.90% | -1.23% | -2.88% | -9,400.00% |
| Issuance of Common Stock | -- | -- | 501.03% | 2,127.08% | -56.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 436.47% | -132.02% | 902.11% | 55.27% | -1,549.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.68% | -340.02% | -297.16% | 111.08% | 51.54% |